Related Experiment Video
Updated: May 21, 2026
08:57
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
MMP2 expression is a prognostic marker for primary melanoma patients
Anand Rotte1, Magdalena Martinka, Gang Li
1Department of Dermatology and Skin Science, Jack Bell Research Centre, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada.
Cellular Oncology (Dordrecht, Netherlands)
|June 7, 2012
Summary
Strong matrix metalloproteinase 2 (MMP2) expression indicates poorer survival in melanoma patients. MMP2 is an independent prognostic factor, correlating with tumor progression and p-Akt status.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Matrix metalloproteinase 2 (MMP2) is a collagenase implicated in tumor growth and invasion.
- Elevated MMP2 aids tumor progression by degrading the extracellular matrix.
Purpose of the Study:
- To investigate MMP2 expression across melanoma stages.
- To determine the prognostic significance of MMP2 expression in melanoma.
- To analyze the correlation between MMP2 and p-Akt status.
Main Methods:
- Tissue microarray and immunohistochemistry were used to assess MMP2 expression in 482 melanoma and 149 nevus biopsies.
- Kaplan-Meier survival analysis and Cox regression were employed to evaluate prognostic significance.
- MMP2 expression was correlated with p-Akt status in 92 cases.
Main Results:
- Strong MMP2 expression was significantly higher in primary (25%) and metastatic melanoma (43%) compared to nevi (5-10%).
- Patients with strong MMP2 expression exhibited significantly poorer survival.
- MMP2 expression independently predicted patient survival and was associated with p-Akt status.
Conclusions:
- Strong MMP2 staining is linked to worse melanoma patient survival.
- MMP2 serves as an independent molecular prognostic factor for primary melanoma.
